randomized trial – Medxy AI

Acute Effects of Cannabis Inhalation on Cardiac Ectopy, Physical Activity, Sleep, and Glucose: A Synthesis of Clinical Evidence and Mechanistic Insights

By MedXY 08/15/2026

This review integrates recent randomized trial data with observational studies to clarify cannabis inhalation's acute impact on cardiac ectopy, physical activity, sleep, and glucose, highlighting complex arrhythmia associations and clinical implications.

Diabetes & Endocrinology Internal Medicine news

Enhancing Preventive Screening Uptake: EHR Portal Messages Boost Mammography Rates

By MedXY 07/02/2026

Iterative redesign of electronic health record (EHR) portal reminders significantly improved mammography screening adherence in an outpatient setting, demonstrating the value of concise messages with scheduling links, while retinal and HbA1c reminders showed no effect.

Cardiology Critical Care news

High-Dose Vitamin C After Cardiac Arrest: Promise Meets a Negative Signal in VITaCCA

By MedXY 06/19/2026

In a multicenter phase 2 trial, early intravenous vitamin C did not improve post-cardiac arrest organ dysfunction and the 10 g dose was associated with worse outcomes, including renal, cardiac, and neurologic signals.

Diabetes & Endocrinology news Public Health

Time-Restricted Eating vs Dietetic Guidance for Glycaemic Outcomes in Adults at Risk of Type 2 Diabetes

By MedXY 06/17/2026

Time-restricted eating performed similarly to individualized dietetic guidance for short-term HbA1c change in adults at risk of type 2 diabetes, but non-inferiority was not confirmed at 12 months. Benefits were small, and adverse events were minor.

Cardiology news

Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Noninferiority Randomized Trial

By MedXY 06/10/2026

A randomized trial found that a two-lead CRT-D system without atrial pacing was noninferior to standard three-lead CRT-D in selected heart failure patients, with fewer atrial lead-related complications.

Internal Medicine Neurology news

Acetazolamide Fails to Improve Gait in Idiopathic Normal Pressure Hydrocephalus: Swedish DRAIN Trial

By MedXY 06/05/2026

In a Swedish randomized trial, low-dose acetazolamide did not improve gait in patients with idiopathic normal pressure hydrocephalus and caused more side effects than placebo, arguing against routine use as medical therapy.

Critical Care Internal Medicine news

Enteral vs IV Magnesium Replacement in Critically Ill Patients: A Randomized Noninferiority Trial

By MedXY 06/05/2026

A randomized ICU trial found oral/enteral magnesium was not proven noninferior to IV replacement for correcting mild-to-moderate hypomagnesemia, but it lowered urinary magnesium loss, cost, waste, carbon emissions, and IV fluid use.

Emergency Medicine Neurology news

Intravenous Magnesium Sulfate for Acute Nontraumatic Headache in the Emergency Department

By MedXY 05/22/2026

Intravenous magnesium sulfate added to paracetamol increased early headache-treatment success in the emergency department, but the pain relief was modest and below usual clinical importance thresholds. It also reduced rescue analgesia needs while causing slightly more mild side effects.

Critical Care General Surgery news

ABRUPT2 Trial: 5% Albumin Reduced Fluid Requirements in Major Burn Resuscitation

By MedXY 05/20/2026

ABRUPT2 found that adding 5% albumin to lactated Ringer’s significantly reduced fluid needs in the first 48 hours after major burns, without clear differences in mortality, kidney injury, or healing time.

Diabetes & Endocrinology news Public Health

Produce Prescription for Diabetes Falls Short in Improving Health Outcomes

By MedXY 04/21/2026

A randomized trial found that a $80 monthly produce prescription did not significantly improve HbA1c levels or reduce healthcare utilization in diabetic patients at risk of food insecurity.

Cardiology news Psychiatry

Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial

By MedXY 12/14/2025

A 3‑arm randomized trial in 524 adults with congenital heart disease found a 4‑week tailored digital emotion‑regulation program produced moderate improvements in emotion regulation and multiple psychosocial outcomes versus usual care; a general program showed delayed, smaller benefits.

news Pediatrics

Supplemental Donor Human Milk Did Not Speed Full Enteral Feeding in Moderate–Late Preterm Infants: Results From a Multisite Randomized Trial

By MedXY 12/14/2025

In a blinded multisite RCT of 201 moderate–late preterm infants, short-term supplementation with pasteurized donor human milk versus term formula did not shorten time to full enteral feeds; donor milk was associated with slower regain of birth weight.

Cardiology Critical Care news

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

By MedXY 12/12/2025

A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarkers of gut, renal, hepatic injury or inflammation.

Anesthesiology General Surgery news Rehabilitation Medicine

Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT

By MedXY 12/08/2025

A pragmatic multicenter randomized trial found that coach-supported, home-based multimodal prehabilitation before elective noncardiac surgery did not reduce 30-day postoperative disability or in-hospital complications in older adults with frailty; higher adherence signaled possible benefit for disability outcomes.

news Respiratory

Morphine Does Not Relieve Chronic Breathlessness: The MABEL Trial Finds No Benefit and Signals More Harms

By MedXY 11/24/2025

A UK multicentre randomized placebo‑controlled trial (MABEL) showed no improvement in worst breathlessness with low‑dose oral morphine versus placebo at 28 days, with more adverse events and withdrawals in the morphine arm.

AI news Oncology

Therapist-Guided e‑Health Cuts Fear of Cancer Recurrence in Colorectal Survivors: A Randomized Trial Shows Clinically Meaningful Benefits

By MedXY 11/19/2025

A Danish RCT of TG‑iConquerFear, a 10‑week therapist‑guided online program for colorectal cancer survivors with clinical fear of cancer recurrence (FCR), reduced FCR scores substantially compared with augmented self‑help at 3 months; the between‑group effect was clinically meaningful (Cohen d 0.62).

Infectious Diseases Internal Medicine Neurology news

Remote Cognitive Training, Structured Rehabilitation and tDCS Failed to Improve Self‑Reported Cognitive Symptoms in Long COVID: Results from a 5‑Arm Phase 2 Randomized Trial

By MedXY 11/18/2025

A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑reported cognitive symptoms in long COVID.

news Oncology

Genomically Matched Therapy Improves Response and PFS Across Advanced Solid Tumors: Phase 2 ROME Trial

By MedXY 11/12/2025

The randomized phase 2 ROME trial showed that genomically matched, MTB-guided therapy increased overall response rate and progression-free survival versus standard care in heavily pretreated advanced solid tumors, supporting a tumor-agnostic precision oncology strategy despite unchanged overall survival due to crossover.

news Pediatrics

Atosiban Did Not Improve Neonatal Outcomes for Threatened Preterm Birth at 30–34 Weeks: Results from the Multicentre APOSTEL 8 Trial

By MedXY 11/11/2025

In the APOSTEL 8 randomized trial, intravenous atosiban did not reduce a composite of perinatal mortality and severe neonatal morbidity versus placebo for threatened preterm birth at 30+0–33+6 weeks.

Cardiology Internal Medicine news

Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial

By MedXY 11/08/2025

The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.